Barbara K. Finck, M.D., Chief Medical Officer, has over 20 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings in multiple therapeutic areas. She received her rheumatology training at University of California, San Francisco, CA, (UCSF) where she studied the effects of CTLA4-Ig (subsequently developed and marketed as Orencia®) in a murine lupus nephritis model. She has held senior level positions in several biopharmaceutical companies including ALZA (medical director for early clinical development of Ditropan-XL®), Immunex (lead medical director for the phase III clinical development of Enbrel® in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis), Eos Biotechology (VP, Clinical Development) and PDL Biopharma (VP, Clinical Development), and Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer).
Barbara K. Finck, M.D., Chief Medical Officer, has over 20 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings in multiple therapeutic areas. She received her rheumatology training at University of California, San Francisco, CA, (UCSF) where she studied the effects of CTLA4-Ig (subsequently developed and marketed as Orencia®) in a murine lupus nephritis model. She has held senior level positions in several biopharmaceutical companies including ALZA (medical director for early clinical development of Ditropan-XL®), Immunex (lead medical director for the phase III clinical development of Enbrel® in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis), Eos Biotechology (VP, Clinical Development) and PDL Biopharma (VP, Clinical Development), and Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer).